• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Afreen Idris Shariff: Cancer Care Can Transform Through e-Consults

Commentary
Video

Afreen Shariff, MD, MBBS, Duke Cancer Institute, discusses the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.

At the recent Association of Community Cancer Centers’ 40th National Oncology Conference, held October 4-6 in Austin, Texas, Afreen Shariff, MD, MBBS, director at Duke Endo-Oncology Program, Duke Endocrinology, Duke Cancer Institute, sat down for a conversation with The American Journal of Managed Care® to discuss both the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.

Here she discusses for whom and in what conditions e-consults are a potential mode of care access.

Transcript

Are there specific patient populations or medical conditions in which e-consults can be particularly beneficial?

I think any area within cancer care can be transformed through e-consults, whether it is psychiatry, psychology care. I think the more niche you are in practice—in the sense that if it is a cardiologist that specializes in cancer therapies and cancer care, or if it is a nephrologist that specializes in cancer therapies and kind of cancer toxicities—depending on what the needs are of the practice, really, defining that and matching that with the experts around the country is where electronic consults can be very helpful. Anywhere where you identify poor access is an opportunity where electronic consults can be very well utilized.

Related Videos
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Dan Nardi
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.